You are correct, it was up 26%...based on a small number and a precipitous drop based on past trial results and ambiguous Pr’s. This mornings PR appears to be me net positive but what it lacks is the concern. Where does it say: EUA applied for? FDA approved? Trial size significant? Actually, does it mention meeting the primary or secondary endpoint? I don’t believe it does. It’s a Nader-math PR that slices and dices to accentuate potential positive while leaving the remainder out.
Here’s a quote from the PR:
"We will expediently submit an update with the above 14-day benefit to the U.S. FDA, Health Canada, and MHRA and will work closely with regulators in other countries. The Company believes this new information bolsters the case for immediate use of leronlimab for critically ill patients. Furthermore, we believe these results suggest that to see maximum effect of leronlimab at day 28, we must use three to four doses of leronlimab and not just two doses, as was the case with CD12 (day zero and day 7 only)
Do you see what they’re submitting? An update! An update to what? The non-existent “conditional EUA”. Shouldn’t this emphatically say that Cytodyn is moving for immediate approval? Also, the PR is obviously written from Cytodyn’s perspective and laced with “we believe”.
There is no substantive assertion to back that up. Why doesn’t it say: “the CRO or FDA CONFIRMED our findings?”
Personally, I don’t see this price holding. I think there are many longs looking at this spike as a gift and will take money off the table. We all have opinions: the market and share price will be the ultimate decider.
Best to you!
Grip
